marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-09-2024
Neoleukin Therapeutics Balance Sheet 2011-2024 | NLTX
Annual Balance Sheet Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-146 M | -81.3 M | -141 M | -193 M | -142 M | -76.9 M | -52 M | -32.3 M | -39.5 M | -14.9 M | -8.72 M | -2 M | - |
Long Term Debt |
65 K | 66 K | 67 K | 11.3 K | - | - | - | - | - | - | 2.04 M | - | - |
Long Term Debt Current |
2.56 M | 678 K | 1.17 M | 659 K | 556 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 11.4 M | 593 K | 319 K | 486 K | 197 K | 131 K | 72.3 K | 2.27 M | 53.1 M | - |
Total Current Liabilities |
23 M | 6.65 M | 8.64 M | 7.89 M | 4.74 M | 4.63 M | 11 M | 9.52 M | 4.79 M | 5.2 M | - | - | - |
Total Liabilities |
36.5 M | 10.6 M | 20.4 M | 19.3 M | 5.34 M | 4.95 M | 11.4 M | 9.72 M | 4.92 M | 5.28 M | 4.89 M | 53.4 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-187 M | -151 M | -393 M | -333 M | -300 M | -230 M | -199 M | -148 M | -111 M | -89.4 M | -63.6 M | -51.6 M | - |
Total Assets |
223 M | 109 M | 163 M | 211 M | 147 M | 77.6 M | 110 M | 154 M | 113 M | 41.4 M | 15.6 M | 2.34 M | - |
Cash and Cash Equivalents |
148 M | 82 M | 142 M | 193 M | 143 M | 76.9 M | 52 M | 32.3 M | 39.5 M | 14.9 M | 11 M | 2 M | - |
Book Value |
186 M | 98.6 M | 143 M | 191 M | 142 M | 72.7 M | 98.9 M | 145 M | 108 M | 36.1 M | 10.8 M | -51.1 M | - |
Total Shareholders Equity |
186 M | -146 M | 143 M | 191 M | 142 M | 72.7 M | 98.9 M | 145 M | 108 M | 36.1 M | -65.7 M | -51.1 M | - |
All numbers in USD currency
Quarterly Balance Sheet Neoleukin Therapeutics
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
53 K | 65 K | 5 K | 6 K | 7 K | 233 K | 9 K | 10 K | 66 K | 67 K | 68 K | 68 K | 122 K | 108 K | 108 K | 108 K | 108 K | 146 K | 146 K | 146 K | 146 K | 6 K | 6 K | 6 K | 6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
24.8 M | 36.5 M | 14.4 M | 14.4 M | 17.1 M | 21.6 M | 20.9 M | 20.3 M | 19 M | 20.4 M | 21.1 M | 20 M | 21.1 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 5.34 M | 5.34 M | 5.34 M | 5.34 M | 4.95 M | 4.95 M | 4.95 M | 4.95 M | 11.4 M | 11.4 M | 11.4 M | 11.4 M | 9.72 M | 9.72 M | 9.72 M | 9.72 M | 4.92 M | 4.92 M | 4.92 M | 4.92 M | 5.28 M | 5.28 M | 5.28 M | 5.28 M | 7.48 M | 7.48 M | 7.48 M | 7.48 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-223 M | -187 M | -472 M | -467 M | -465 M | -451 M | -438 M | -425 M | -409 M | -393 M | -378 M | -363 M | -348 M | -333 M | -333 M | -333 M | -333 M | -300 M | -300 M | -300 M | -300 M | -230 M | -230 M | -230 M | -230 M | -199 M | -199 M | -199 M | -199 M | -148 M | -148 M | -148 M | -148 M | -111 M | -111 M | -111 M | -111 M | -89.4 M | -89.4 M | -89.4 M | -89.4 M | -65.7 M | -65.7 M | -65.7 M | - | - | - | - | - | - | - | - | - |
Total Assets |
180 M | 223 M | 89.6 M | 94 M | 98.5 M | 116 M | 127 M | 137 M | 149 M | 163 M | 176 M | 187 M | 200 M | 211 M | 211 M | 211 M | 211 M | 147 M | 147 M | 147 M | 147 M | 77.6 M | 77.6 M | 77.6 M | 77.6 M | 110 M | 110 M | 110 M | 110 M | 154 M | 154 M | 154 M | 154 M | 113 M | 113 M | 113 M | 113 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
111 M | 148 M | 25.2 M | 59 M | 35.5 M | 37.9 M | 41.2 M | 78.4 M | 129 M | 142 M | 156 M | 165 M | 178 M | 193 M | 193 M | 193 M | 193 M | 143 M | 143 M | 143 M | 143 M | 76.9 M | 76.9 M | 76.9 M | 76.9 M | 52 M | 52 M | 52 M | 52 M | 32.3 M | 32.3 M | 32.3 M | 32.3 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 11 M | 11 M | 11 M | 11 M | 2 M | - | - | - | 9.24 M | - | - | - |
Book Value |
155 M | 186 M | 75.2 M | 79.6 M | 81.4 M | 94.3 M | 106 M | 117 M | 130 M | 143 M | 155 M | 167 M | 179 M | 191 M | 191 M | 191 M | 191 M | 142 M | 142 M | 142 M | 142 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 98.9 M | 98.9 M | 98.9 M | 98.9 M | 145 M | 145 M | 145 M | 145 M | 108 M | 108 M | 108 M | 108 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 8.17 M | 8.17 M | 8.17 M | 8.17 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
155 M | 186 M | 75.2 M | -169 M | 81.4 M | 94.3 M | 106 M | 117 M | 130 M | 143 M | 155 M | 167 M | 179 M | 191 M | 191 M | 191 M | 191 M | 142 M | 142 M | 142 M | 142 M | 72.7 M | 72.7 M | 72.7 M | 72.7 M | 98.9 M | 98.9 M | 98.9 M | 98.9 M | 145 M | 145 M | 145 M | 145 M | 108 M | 108 M | 108 M | 108 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | -65.7 M | -65.7 M | -65.7 M | -65.7 M | -51.1 M | - | - | - | -39.3 M | - | - | - |
All numbers in USD currency